Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE

Idir Ouzaid (1, 2) , Karim Bensalah (3, 4)

1 Service d'urologie [Mondor]
2 IMRB - Institut Mondor de Recherche Biomédicale
3 CHU Pontchaillou [Rennes]
4 LTSI - Laboratoire Traitement du Signal et de l'Image

Referred to by Matteo Santoni, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Alberto Briganti, Francesco Montorsi, Rodolfo Montironi, Daniele Santini Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542–3 European Urology, Available online 1 October 2015

Domains: Life Sciences [q-bio]; Bioengineering

Idir Ouzaid, Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. European Urology, 2015, 68 (3), pp.542--543. ⟨10.1016/j.eururo.2015.04.042⟩. ⟨hal-01260239⟩